Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.

Fumet, Jean-David; Isambert, Nicolas; Hervieu, Alice; Zanetta, Sylvie; Guion, Jean-Florian; Hennequin, Audrey; Rederstorff, Emilie; Bertaut, Aurélie; Ghiringhelli, Francois

Fumet, Jean-David; Isambert, Nicolas; Hervieu, Alice; Zanetta, Sylvie; Guion, Jean-Florian; Hennequin, Audrey; Rederstorff, Emilie; Bertaut, Aurélie; Ghiringhelli, Francois.

Afiliação

Fumet JD; Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France.
Isambert N; Research Platform in Biological Oncology, Georges Francois Leclerc Center, Dijon, France.
Hervieu A; University of Burgundy-Franche Comté, Dijon, France.
Zanetta S; Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France.
Guion JF; Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France.
Hennequin A; Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France.
Rederstorff E; Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France.
Bertaut A; Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France.
Ghiringhelli F; Department of Epidemiology and Biostatistics, Georges François Leclerc Center, Dijon, France.

ESMO Open ; 3(4): e000375, 2018.

Article em En | MEDLINE | ID: mdl-29942666

Palavras-chave

chemotherapy; colorectal cancer; durvalumab; immunotherapy; tremelimumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: ESMO Open Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google